DNMT3B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
S-Adenosylhomocysteine (SCHEMBL753710)	0.78	10/20
SCHEMBL1457737	0.76	10/20
SCHEMBL1458224	0.60	10/20
SCHEMBL571843	0.57	7/20
SCHEMBL571844	0.57	7/20
SCHEMBL571845	0.57	7/20
S-Adenosylhomocysteine (SCHEMBL8836)	1.00	6/20
S-Adenosylhomocysteine (SCHEMBL804238)	1.00	6/20
SCHEMBL536435	0.79	5/20
SCHEMBL536436	0.79	5/20
SCHEMBL535881	0.66	5/20
SCHEMBL535882	0.66	5/20
SCHEMBL536395	0.64	5/20
SCHEMBL536396	0.64	5/20
SCHEMBL542384	0.62	5/20
SCHEMBL708894	0.59	5/20
SCHEMBL536404	0.54	5/20
SCHEMBL1458203	0.37	5/20
SCHEMBL536086	0.84	4/20
SCHEMBL536054	0.73	4/20

Clinical trials — most relevant to DNMT3B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation	PHASE4	COMPLETED
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC	PHASE3	UNKNOWN
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)	PHASE2/PHASE3	COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)	PHASE2	COMPLETED
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome	PHASE1/PHASE2	COMPLETED
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)	PHASE1/PHASE2	RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia	PHASE1	COMPLETED
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	PHASE1	COMPLETED
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)	PHASE1	RECRUITING
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer	PHASE1	SUSPENDED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
Effect of DNMT SNPs on DNA Methylation in Primary ITP	nan	UNKNOWN
DNA Methylation and Perioperative Pain Treatment	nan	COMPLETED
Analysis of DNA Methylation in Spondyloarthritis	nan	COMPLETED
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB)	nan	COMPLETED
A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL	nan	RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Family Resilience Initiative Research Program	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C	nan	UNKNOWN
Exploratory Study of Rectal Mucus for Diagnosing Disease	nan	COMPLETED
Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks	nan	RECRUITING
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a DNMT3B binder may also engage these)

Protein	Name	Similarity
O88509	—	1.000	O88509 →
P0DOY1	—	0.985	P0DOY1 →
Q5R7T9	—	0.980	Q5R7T9 →
Q8BML1	—	0.980	Q8BML1 →
F1RA39	—	0.980	F1RA39 →
Q02395	—	0.979	Q02395 →
Q9Y483	—	0.977	Q9Y483 →
Q4KLT3	—	0.976	Q4KLT3 →
Q1LZ50	—	0.976	Q1LZ50 →
O94851	—	0.976	O94851 →
F6QZ15	—	0.975	F6QZ15 →
Q8K394	—	0.975	Q8K394 →
Q8BMA3	—	0.975	Q8BMA3 →
Q8BJ37	—	0.975	Q8BJ37 →
F1MF74	—	0.975	F1MF74 →
Q08D35	—	0.975	Q08D35 →
Q9CWR8	—	0.974	Q9CWR8 →
DNMT3L	DNA (cytosine-5)-methyltransferase 3-like	0.974	landscape →
Q8CG07	—	0.974	Q8CG07 →
P51432	—	0.974	P51432 →
EEF2K	Eukaryotic elongation factor 2 kinase	0.974	landscape →
Q5RHD1	—	0.974	Q5RHD1 →
D4A1F2	—	0.974	D4A1F2 →
Q3UWM4	—	0.973	Q3UWM4 →
Q80TJ7	—	0.973	Q80TJ7 →
Q9D0L8	—	0.973	Q9D0L8 →
BRAP	BRCA1-associated protein	0.973	landscape →
Q5BJT6	—	0.973	Q5BJT6 →
Q5ZLV4	—	0.973	Q5ZLV4 →
Q08BR4	—	0.973	Q08BR4 →